A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

This early-phase study is testing DXC008 — a new drug — in patients with prostate cancer that has spread and is no longer responding to hormone therapy (called metastatic castration-resistant prostate cancer, or mCRPC), as well as other solid tumours that have failed standard treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have a solid tumour (including mCRPC) that has not responded to standard treatments - Your testosterone level is very low (≤50 ng/dL — indicating hormone therapy is working to suppress testosterone) - Your expected survival is at least 6 months and your general health is adequate (ECOG 0–2) - You have measurable disease on scans or at least one metastatic lesion visible on imaging **You may NOT be eligible if...** - Your testosterone level is above the threshold required - You have poor organ function or a serious concurrent illness - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.